Obstructive Hypertrophic Cardiomyopathy clinical trials

Explore recruiting obstructive hypertrophic cardiomyopathy clinical trials.

Recruiting obstructive hypertrophic cardiomyopathy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Obstructive Hypertrophic Cardiomyopathy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adolescents (age 12 years to < 18 years) with Symptomatic Obstructive Hypertrophic Cardiomyopathy (SCOUT-HCM)

Germany, Spain, Italy, Ireland, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

MEMENTO-A Phase 3b/4 Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to assess the impact on Myocardial Structure with Cardiac Magnetic Resonance Imaging (CMR)

Hungary, Finland, Spain, France, Greece, Italy +5 more

Phase III and phase IV (Integrated) EU CTIS Study details

A Phase 2/3 Multicenter, Randomized, Double-blind, Placebo-controlled and Open-label Extension Trial to Evaluate the Efficacy and Safety of Aficamten in a Pediatric Population with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Spain, Italy, Ireland

Phase II and Phase III (Integrated) EU CTIS Study details

Short and long-term Hemodynamic and Physiological Effects of Mavacamten in Obstructive Hypertrophic Cardiomyopathy

Sweden

Therapeutic use (Phase IV) EU CTIS Study details

A Global Phase 2b, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients with Symptomatic Non Obstructive Hypertrophic Cardiomyopathy – FORTITUDE-HCM

Austria, Germany, Belgium, France, Portugal, Spain +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

BMS CV027-031, A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy

Czechia, Belgium, Norway, Spain, Poland, Hungary +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Obstructive Hypertrophic Cardiomyopathy trials by city

Obstructive Hypertrophic Cardiomyopathy in Toronto Obstructive Hypertrophic Cardiomyopathy in Vancouver Obstructive Hypertrophic Cardiomyopathy in Montreal Obstructive Hypertrophic Cardiomyopathy in Calgary Obstructive Hypertrophic Cardiomyopathy in Edmonton Obstructive Hypertrophic Cardiomyopathy in Ottawa Obstructive Hypertrophic Cardiomyopathy in Winnipeg Obstructive Hypertrophic Cardiomyopathy in Quebec City Obstructive Hypertrophic Cardiomyopathy in Hamilton Obstructive Hypertrophic Cardiomyopathy in Kitchener Obstructive Hypertrophic Cardiomyopathy in London Obstructive Hypertrophic Cardiomyopathy in Halifax Obstructive Hypertrophic Cardiomyopathy in New York Obstructive Hypertrophic Cardiomyopathy in Los Angeles Obstructive Hypertrophic Cardiomyopathy in Chicago Obstructive Hypertrophic Cardiomyopathy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease